NO20060632L - Nye forbindelser og sammensettinger som omfatter steroler og/eller stanoler og kolesterolbiosynteseinhibitorer og anvendelse av disse i behandling eller forebygging av en rekke sykdommer og tilstander - Google Patents

Nye forbindelser og sammensettinger som omfatter steroler og/eller stanoler og kolesterolbiosynteseinhibitorer og anvendelse av disse i behandling eller forebygging av en rekke sykdommer og tilstander

Info

Publication number
NO20060632L
NO20060632L NO20060632A NO20060632A NO20060632L NO 20060632 L NO20060632 L NO 20060632L NO 20060632 A NO20060632 A NO 20060632A NO 20060632 A NO20060632 A NO 20060632A NO 20060632 L NO20060632 L NO 20060632L
Authority
NO
Norway
Prior art keywords
compositions
stanols
conditions
sterols
diseases
Prior art date
Application number
NO20060632A
Other languages
English (en)
Inventor
Tatjana Lukic
James P Kutney
Haydn P Pritchard
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of NO20060632L publication Critical patent/NO20060632L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer i et aspekt, nye forbindelser som innbefatter steroler og/eller stanoler og biosynteseinhibitorer, som inkluderer salter av disse forbindelsene og solvater og prodrugs av disse forbindelsene og/eller salter. I et annet aspekt tilveiebringer foreliggende oppfinnelse sammensetninger som innbefatter minst en sterol og/eller stanolester og minst en kolesterolbiosynteseinhibitor. Også tilveiebrakt er fremgangsmåter for behandling eller hindring av et antall sykdonuner, tilstander og forstyrrelser ved å administrere forbindelsene eller sammensetningene tilveiebrakt heri.
NO20060632A 2003-07-09 2006-02-09 Nye forbindelser og sammensettinger som omfatter steroler og/eller stanoler og kolesterolbiosynteseinhibitorer og anvendelse av disse i behandling eller forebygging av en rekke sykdommer og tilstander NO20060632L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61545603A 2003-07-09 2003-07-09
PCT/CA2004/000999 WO2005005453A2 (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.

Publications (1)

Publication Number Publication Date
NO20060632L true NO20060632L (no) 2006-04-06

Family

ID=34062381

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060632A NO20060632L (no) 2003-07-09 2006-02-09 Nye forbindelser og sammensettinger som omfatter steroler og/eller stanoler og kolesterolbiosynteseinhibitorer og anvendelse av disse i behandling eller forebygging av en rekke sykdommer og tilstander

Country Status (13)

Country Link
EP (1) EP1644399A2 (no)
JP (1) JP2007525470A (no)
KR (1) KR20060052792A (no)
CN (1) CN1832957A (no)
AU (1) AU2004255285A1 (no)
BR (1) BRPI0412439A (no)
CA (1) CA2531836A1 (no)
MX (1) MXPA06000326A (no)
NO (1) NO20060632L (no)
NZ (1) NZ545087A (no)
PL (1) PL379516A1 (no)
RU (1) RU2006103797A (no)
WO (1) WO2005005453A2 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
KR100886466B1 (ko) * 2006-09-12 2009-03-04 (주)한국씨엔에스팜 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20150013232A (ko) * 2012-05-07 2015-02-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133
KR20140081339A (ko) * 2012-12-21 2014-07-01 부경대학교 산학협력단 푸코스테롤을 유효성분으로 포함하는 퇴행성 신경질환 예방 또는 치료용 약제학적 조성물
WO2014179756A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
KR20170101940A (ko) 2014-12-09 2017-09-06 워쏘우 오르쏘페딕 인코포레이티드 스테롤 관련 화합물 및 방법
CN104434927A (zh) * 2014-12-16 2015-03-25 吉林农业大学 丙二酸双环戊烷并多氢菲酯b在制备降血压药物中的应用
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
CN105055404B (zh) * 2015-08-19 2017-07-18 四川大学 Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途
CN105087609B (zh) * 2015-08-19 2018-10-23 四川大学 一种重组慢病毒及其在制备治疗可卡因成瘾的药物中的用途
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
KR102139994B1 (ko) * 2017-10-25 2020-07-31 대구대학교 산학협력단 스티그마스테롤을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
CN113143935B (zh) * 2021-02-01 2022-10-11 广东药科大学 豆甾醇在制备改善心肌肥厚的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
AU5383700A (en) * 1999-06-23 2001-01-31 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease

Also Published As

Publication number Publication date
MXPA06000326A (es) 2006-03-30
WO2005005453A2 (en) 2005-01-20
AU2004255285A1 (en) 2005-01-20
BRPI0412439A (pt) 2006-09-05
PL379516A1 (pl) 2006-10-02
WO2005005453A3 (en) 2005-06-09
EP1644399A2 (en) 2006-04-12
KR20060052792A (ko) 2006-05-19
JP2007525470A (ja) 2007-09-06
RU2006103797A (ru) 2006-07-27
NZ545087A (en) 2009-10-30
CN1832957A (zh) 2006-09-13
CA2531836A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
NO20060632L (no) Nye forbindelser og sammensettinger som omfatter steroler og/eller stanoler og kolesterolbiosynteseinhibitorer og anvendelse av disse i behandling eller forebygging av en rekke sykdommer og tilstander
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
NO20082075L (no) Anti-hyperkolesterolemiske forbindelser
WO2006138163A3 (en) Anti-hypercholesterolemic compounds
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20050016L (no) Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
WO2005062824A8 (en) Anti-hypercholesterolemic compounds
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
NO20074647L (no) 3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
EP2332527A3 (en) Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20070876L (no) Apolipoprotein A1 mimetics og anvendelser derav.
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20085323L (no) Smeltede, tricykliske sulfonamidinhibitorer av gammasekretase
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
WO2023004102A3 (en) Compositions and methods for inhibition of ras
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
WO2005046797A3 (en) Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application